Icahn Blasts Forest Labs' Nondisclosure Of FDA Letter

Law360, New York (August 14, 2012, 3:38 PM EDT) -- Activist investor Carl Icahn on Monday turned up the heat in his proxy fight with Forest Laboratories Inc., ripping the drugmaker for not disclosing to investors a recent U.S. Food and Drug Administration warning letter over alleged off-label promotion of its chronic obstructive pulmonary disease drug Daliresp.

With Forest's annual shareholders' meeting set for Wednesday, Icahn, who is running another minority slate of company director nominees after a failed proxy fight last year, criticized Forest over the warning letter made public by the FDA last Tuesday...
To view the full article, register now.